Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Trial of Asthma Patient Education (TAPE)

This study has been completed.
Sponsor:
Collaborator:
Information provided by:
American Lung Association Asthma Clinical Research Centers
ClinicalTrials.gov Identifier:
NCT00148408
First received: September 6, 2005
Last updated: April 28, 2010
Last verified: September 2006
  Purpose

The purpose of this research study is to investigate the way that educational approaches and presentation of a drug may affect the response to montelukast and placebo (an inactive medication) in subjects with asthma.


Condition Intervention Phase
Asthma
Drug: Montelukast
Behavioral: Education
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Official Title: Trial of Asthma Patient Education (TAPE)

Resource links provided by NLM:


Further study details as provided by American Lung Association Asthma Clinical Research Centers:

Primary Outcome Measures:
  • Morning peak expiratory flow

Secondary Outcome Measures:
  • Spirometry
  • Asthma diaries
  • Asthma questionnaires (Asthma Control Score, Asthma Symptom Utility Index, Asthma Quality of Life)
  • Generic health quality of life (SF-36)
  • Shortness of Breath Questionnaire
  • Adherence monitoring

Estimated Enrollment: 600
Study Start Date: December 2003
Study Completion Date: December 2005
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Detailed Description:

This is a study of the effects of education and drug presentation on efficacy of montelukast and placebo in asthma. This trial will answer the following questions: 1) Is there a true placebo response in asthma that is not due to non-specific factors? 2) Can the placebo effect in asthma be augmented by interventions that increase expectancy of benefit? 3) Can interventions that increase expectancy augment the effect of active treatment? 4) Are placebo effects additive or interactive with treatment effects?

  Eligibility

Ages Eligible for Study:   15 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 15 or older
  • physician diagnosed asthma
  • regular use of prescribed asthma medication over preceding year
  • post-bronchodilator FEV1 of at least 75% of predicted
  • inadequate asthma control over preceding two months

Exclusion Criteria:

  • current or past smoking (greater than 10 pack-years)
  • serious asthma exacerbation within previous three months
  • regular use of oral corticosteroids
  • history of respiratory failure due to asthma
  • current use of montelukast or history of adverse reaction to montelukast
  • concomitant interfering medical condition
  • participation in another clinical trial
  • inability or unwillingness to perform study procedures
  • pregnancy, lack of effective contraception (when appropriate), lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00148408

  Show 20 Study Locations
Sponsors and Collaborators
American Lung Association Asthma Clinical Research Centers
Investigators
Study Chair: Nicholas Anthonisen, MD University of Winnipeg
  More Information

Additional Information:
No publications provided by American Lung Association Asthma Clinical Research Centers

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00148408     History of Changes
Other Study ID Numbers: ALAACRC-04
Study First Received: September 6, 2005
Last Updated: April 28, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by American Lung Association Asthma Clinical Research Centers:
Asthma
Placebo
Education

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Lung Diseases
Lung Diseases, Obstructive
Respiratory Hypersensitivity
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 20, 2014